1695 related articles for article (PubMed ID: 23201472)
21. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Rosenfeld CS; Bolwell B; LeFever A; Taylor R; List A; Fay J; Collins R; Andrews F; Pallansch P; Schuster MW; Resta D; Levitt D; Nemunaitis J
Bone Marrow Transplant; 1996 Feb; 17(2):179-83. PubMed ID: 8640163
[TBL] [Abstract][Full Text] [Related]
22. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
24. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.
Gyger M; Stuart RK; Perreault C
Bone Marrow Transplant; 2000 Jul; 26(1):1-16. PubMed ID: 10918400
[TBL] [Abstract][Full Text] [Related]
25. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
26. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
27. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
28. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
[TBL] [Abstract][Full Text] [Related]
29. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation.
Lane TA; Law P; Maruyama M; Young D; Burgess J; Mullen M; Mealiffe M; Terstappen LW; Hardwick A; Moubayed M
Blood; 1995 Jan; 85(1):275-82. PubMed ID: 7528570
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
32. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
[TBL] [Abstract][Full Text] [Related]
34. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors.
Gazitt Y; Shaughnessy P; Devore P
J Hematother Stem Cell Res; 2001 Feb; 10(1):177-86. PubMed ID: 11276371
[TBL] [Abstract][Full Text] [Related]
35. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
36. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
[TBL] [Abstract][Full Text] [Related]
37. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
[TBL] [Abstract][Full Text] [Related]
38. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
39. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation.
MacDonald KP; Rowe V; Filippich C; Johnson D; Morris ES; Clouston AD; Ferrara JL; Hill GR
Biol Blood Marrow Transplant; 2004 Jun; 10(6):373-85. PubMed ID: 15148491
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
Sallerfors B; Olofsson T; Lenhoff S
Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
